Sarepta Therapeutics Inc

Find Ratings Reports
SRPT : NASDAQ : Health Care
$35.02 | %
Today's Range: 34.2814 - 35.433
Avg. Daily Volume: 1902500.0
06/23/17 - 4:00 PM ET

Financial Analysis


SAREPTA THERAPEUTICS INC's gross profit margin for the first quarter of its fiscal year 2017 has significantly decreased when compared to the same period a year ago. Even though it increased sales and net income significantly, the company was unable to grow at a faster pace than its industry competitors. SAREPTA THERAPEUTICS INC is extremely liquid. Currently, the Quick Ratio is 5.39 which clearly shows the ability to cover any short-term cash needs. SRPT managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.

At the same time, stockholders' equity ("net worth") has greatly increased by 208.81% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY17 Q1 FY16
Net Sales ($mil)16.340.0
EBITDA ($mil)-37.37-57.77
EBIT ($mil)-39.01-59.17
Net Income ($mil)84.09-59.77


Balance Sheet Q1 FY17 Q1 FY16
Cash & Equiv. ($mil)390.31139.85
Total Assets ($mil)511.53213.36
Total Debt ($mil)13.6920.98
Equity ($mil)429.14138.96


Profitability Q1 FY17 Q1 FY16
Gross Profit Margin-228.690.0
EBITDA Margin-228.680.0
Operating Margin-238.70.0
Sales Turnover0.040.01
Return on Assets-24.12-102.28
Return on Equity-28.75-157.05
Debt Q1 FY17 Q1 FY16
Current Ratio6.132.91
Debt/Capital0.030.13
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q1 FY17 Q1 FY16
Shares outstanding (mil)54.9445.77
Div / share0.00.0
EPS1.5-1.31
Book value / share7.813.04
Institutional Own % n/a n/a
Avg Daily Volume1883726.02552435.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Conducting a second comparison, its price-to-book ratio of 4.54 indicates a premium versus the S&P 500 average of 3.09 and a significant discount versus the industry average of 11.09. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, SAREPTA THERAPEUTICS INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
SRPT NM Peers 41.96   SRPT NM Peers 43.61

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

SRPT's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

SRPT's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
SRPT NM Peers 26.44   SRPT NA Peers 0.54

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

SRPT's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
SRPT 4.54 Peers 11.09   SRPT 47.11 Peers -9.68

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

SRPT is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

SRPT is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
SRPT 89.58 Peers 172.46   SRPT 1636.87 Peers 462.34

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

SRPT is trading at a significant discount to its industry on this measurement.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

SRPT has a sales growth rate that significantly exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades